Prodrug Strategies in Ocular Drug Delivery

被引：40

作者：

Barot, Megha ^{[1
]}

Bagui, Mahuya ^{[1
]}

Gokulgandhi, Mitan R. ^{[1
]}

Mitra, Ashim K. ^{[1
]}

机构：

[1] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA

来源：

MEDICINAL CHEMISTRY | 2012年 / 8卷 / 04期

关键词：

Prodrug; transporter; receptor; drug delivery; BLOOD-RETINAL BARRIER; AMINO-ACID TRANSPORTER; IN-VITRO EVALUATION; CORNEAL EPITHELIAL-CELLS; PIGMENTED RABBIT CONJUNCTIVA; CARBONIC-ANHYDRASE INHIBITORS; GLYCOPROTEIN-MEDIATED EFFLUX; DIPEPTIDE ESTER PRODRUGS; WATER-SOLUBLE PRODRUGS; FOLATE RECEPTOR-ALPHA;

D O I：

10.2174/157340612801216283

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Poor bioavailability of topically instilled drug is the major concern in the field of ocular drug delivery. Efflux transporters, static and dynamic ocular barriers often possess rate limiting factors for ocular drug therapy. Different formulation strategies like suspension, ointment, gels, nanoparticles, implants, dendrimers and liposomes have been employed in order to improve drug permeation and retention by evading rate limiting factors at the site of absorption. Chemical modification such as prodrug targeting various nutrient transporters (amino acids, peptide and vitamin) has evolved a great deal of interest to improve ocular drug delivery. In this review, we have discussed various prodrug strategies which have been widely applied for enhancing therapeutic efficacy of ophthalmic drugs. The purpose of this review is to provide an update on the utilization of prodrug concept in ocular drug delivery. In addition, this review will highlight ongoing academic and industrial research and development in terms of ocular prodrug design and delivery.

引用

页码：753 / 768

页数：16

共 196 条

[1] (ACYLOXY)ALKYL CARBAMATES AS NOVEL BIOREVERSIBLE PRODRUGS FOR AMINES - INCREASED PERMEATION THROUGH BIOLOGICAL-MEMBRANES [J].

ALEXANDER, J ;

CARGILL, R ;

MICHELSON, SR ;

SCHWAM, H .

JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (02) :318-322

[2] Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea [J].

Anand, BS ;

Mitra, AK .

PHARMACEUTICAL RESEARCH, 2002, 19 (08) :1194-1202

[3] Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea [J].

Anand, BS ;

Nashed, YE ;

Mitra, AK .

CURRENT EYE RESEARCH, 2003, 26 (3-4) :151-163

[4] Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: Interactions with the neutral and cationic amino acid transporter on the corneal epithelium [J].

Anand, BS ;

Katragadda, S ;

Nashed, YE ;

Mitra, AK .

CURRENT EYE RESEARCH, 2004, 29 (2-3) :153-166

[5] Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: Intestinal absorption and liver metabolism [J].

Anand, BS ;

Katragadda, S ;

Mitra, AK .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (02) :659-667

[6] In vivo antiviral efficacy of a dipeptide acyclovir prodrug, val-val-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model [J].

Anand, BS ;

Hill, JM ;

Dey, S ;

Maruyama, K ;

Bhattacharjee, PS ;

Myles, ME ;

Nashed, YE ;

Mitra, AK .

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (06) :2529-2534

[7] Current prodrug strategies via membrane transporters/receptors [J].

Anand, BS ;

Dey, S ;

Mitra, AK .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (06) :607-620

[8] Antiviral activity of ganciclovir elaidic acid ester against herpesviruses [J].

Andrei, G ;

Snoeck, R ;

Neyts, J ;

Sandvold, ML ;

Myhren, F ;

De Clercq, E .

ANTIVIRAL RESEARCH, 2000, 45 (03) :157-167

[9]

[Anonymous], 2003, HYDROLYSIS DRUG PROD

[10] Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration [J].

Atluri, H ;

Anand, BS ;

Patel, J ;

Mitra, AK .

EXPERIMENTAL EYE RESEARCH, 2004, 78 (04) :815-822

← 1 2 3 4 5 6 7 8 9 10 →